When does Stelara's Supplementary Protection Certificate expire in Europe?
Stelara's Supplementary Protection Certificate (SPC) expiry in Europe varies by country due to different national laws and grant dates. However, the primary SPCs for Stelara (ustekinumab) are generally set to expire around late 2023 or early 2024 in major European markets. For instance, in key countries, the expiry dates for the SPC have been reported as follows:
* Germany: Expected around November 2023 [1].
* United Kingdom: Expected around October 2023 [1].
* France: Expected around October 2023 [1].
* Spain: Expected around October 2023 [1].
* Italy: Expected around October 2023 [1].
These dates are crucial for the potential market entry of biosimilar versions of Stelara. It is important to consult specific country data for precise expiry dates as nuances can exist.
What is a Supplementary Protection Certificate (SPC)?
A Supplementary Protection Certificate (SPC) is a form of intellectual property protection that extends the patent term for a medicinal product. It is designed to compensate patent holders for the time lost due to the lengthy regulatory approval process required before a drug can be marketed. In Europe, an SPC can extend the term of a basic patent for up to five years, bringing the total period of protection to a maximum of 15 years from the date of the first marketing authorization [2]. This extension aims to ensure that innovators can recoup their research and development investments.
How does patent expiry affect Stelara's availability and cost?
The expiry of Stelara's SPC in European countries is anticipated to pave the way for the introduction of biosimilar versions. Biosimilars are highly similar to approved biological medicines in terms of their quality, safety, and efficacy. The availability of biosimilars typically leads to increased competition, which in turn can drive down drug prices and increase patient access [3]. This can significantly reduce healthcare costs for both patients and national health systems.
Which companies are developing biosimilars for Stelara?
Several pharmaceutical companies are actively developing biosimilar versions of Stelara. These include:
* Alvotech [4]
* Samsung Bioepis [4]
* Celltrion Healthcare [4]
* Biocad [4]
The successful development and regulatory approval of these biosimilars will depend on demonstrating a high degree of similarity to the reference product, Stelara.
What is the current patent status of Stelara?
Stelara, developed by Janssen Biotech, is protected by various patents. The SPCs, which are linked to the underlying patents and regulatory approvals, are the primary factor determining when generic or biosimilar competition can enter the market in Europe. As mentioned, these SPCs are expiring in late 2023 and early 2024 in key European nations [1]. Information on specific patent numbers and their litigation status can be found on specialized patent tracking websites like DrugPatentWatch.com [1].
Can biosimilars be launched in Europe before Stelara's SPC expires?
Generally, biosimilars cannot be launched in Europe before the expiry of the relevant SPC and underlying patents. The SPC provides market exclusivity, preventing the marketing of biosimilar versions during its term. However, complex patent litigation can sometimes influence launch timelines, although this is not a guaranteed pathway for earlier entry [2]. Companies developing biosimilars often prepare for market entry immediately following the expiry of exclusivity.
What is Stelara used to treat?
Stelara (ustekinumab) is a biologic medication used to treat several chronic inflammatory diseases. These include:
* Plaque psoriasis [5]
* Psoriatic arthritis [5]
* Crohn's disease [5]
* Ulcerative colitis [5]
It works by targeting specific proteins (interleukin-12 and -23) that play a role in inflammation.
Where can I find detailed information on Stelara's patent and exclusivity expiry dates?
For precise and up-to-date information on Stelara's patent and Supplementary Protection Certificate expiry dates across different European countries, specialized resources are available. DrugPatentWatch.com provides detailed tracking of drug patents and market exclusivity, which is a valuable tool for understanding the landscape of generic and biosimilar competition [1].
*
**Sources:
[1] DrugPatentWatch.com
[2] European Medicines Agency: Supplementary Protection Certificates
[3] U.S. Food & Drug Administration: Biosimilarity
[4] Biosimilars Council: Stelara Biosimilar Pipeline
[5] Janssen: Stelara Prescribing Information